Omega Fund Vi Gp Manager, Ltd. - Net Worth and Insider Trading

Omega Fund Vi Gp Manager, Ltd. Net Worth

The estimated net worth of Omega Fund Vi Gp Manager, Ltd. is at least $4 Million dollars as of 2024-11-05. Omega Fund Vi Gp Manager, Ltd. is the of Theseus Pharmaceuticals Inc and owns about 711,479 shares of Theseus Pharmaceuticals Inc (THRX) stock worth over $3 Million. Omega Fund Vi Gp Manager, Ltd. is also the 10% Owner of Spruce Biosciences Inc and owns about 2,161,022 shares of Spruce Biosciences Inc (SPRB) stock worth over $1 Million. Details can be seen in Omega Fund Vi Gp Manager, Ltd.'s Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Omega Fund Vi Gp Manager, Ltd. has not made any transactions after 2021-10-12 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

Transaction Summary of Omega Fund Vi Gp Manager, Ltd.

Omega Fund Vi Gp Manager, Ltd. Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Omega Fund Vi Gp Manager, Ltd. owns 5 companies in total, including Spruce Biosciences Inc (SPRB) , Imago BioSciences Inc (IMGO) , and Theseus Pharmaceuticals Inc (THRX) among others .

Click here to see the complete history of Omega Fund Vi Gp Manager, Ltd.’s form 4 insider trades.

Insider Ownership Summary of Omega Fund Vi Gp Manager, Ltd.

Ticker	Comapny	Transaction Date	Type of Owner
SPRB	Spruce Biosciences Inc	2020-10-14	10 percent owner
IMGO	Imago BioSciences Inc	2021-07-15	10 percent owner
THRX	Theseus Pharmaceuticals Inc	2021-10-12	10 percent owner
		2021-01-06	10 percent owner
		2023-11-02	10 percent owner

Omega Fund Vi Gp Manager, Ltd. Latest Holdings Summary

Omega Fund Vi Gp Manager, Ltd. currently owns a total of 2 stocks. Among these stocks, Omega Fund Vi Gp Manager, Ltd. owns 711,479 shares of Theseus Pharmaceuticals Inc (THRX) as of October 12, 2021, with a value of $3 Million and a weighting of 71.22%. Omega Fund Vi Gp Manager, Ltd. also owns 2,161,022 shares of Spruce Biosciences Inc (SPRB) as of October 14, 2020, with a value of $1 Million and a weighting of 28.78%.

Latest Holdings of Omega Fund Vi Gp Manager, Ltd.

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
THRX	Theseus Pharmaceuticals Inc	2021-10-12	711,479	4.06	2,888,605
SPRB	Spruce Biosciences Inc	2020-10-14	2,161,022	0.54	1,167,168

Holding Weightings of Omega Fund Vi Gp Manager, Ltd.

Omega Fund Vi Gp Manager, Ltd. Form 4 Trading Tracker

According to the SEC Form 4 filings, Omega Fund Vi Gp Manager, Ltd. has made a total of 1 transactions in Theseus Pharmaceuticals Inc (THRX) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Theseus Pharmaceuticals Inc is the acquisition of 187,500 shares on October 12, 2021, which cost Omega Fund Vi Gp Manager, Ltd. around $3 Million.

According to the SEC Form 4 filings, Omega Fund Vi Gp Manager, Ltd. has made a total of 1 transactions in Spruce Biosciences Inc (SPRB) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Spruce Biosciences Inc is the acquisition of 250,000 shares on October 14, 2020, which cost Omega Fund Vi Gp Manager, Ltd. around $4 Million.

Insider Trading History of Omega Fund Vi Gp Manager, Ltd.

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Omega Fund Vi Gp Manager, Ltd. Trading Performance

GuruFocus tracks the stock performance after each of Omega Fund Vi Gp Manager, Ltd.'s buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Omega Fund Vi Gp Manager, Ltd. is -1.19%. GuruFocus also compares Omega Fund Vi Gp Manager, Ltd.'s trading performance to market benchmark return within the same time period. The performance of stocks bought by Omega Fund Vi Gp Manager, Ltd. within 3 months outperforms 1 times out of 2 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Omega Fund Vi Gp Manager, Ltd.'s insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Omega Fund Vi Gp Manager, Ltd.

Average Return

Average return per transaction

Outperforming Transactions

0 out of 2 outperforming transactions.

Each transaction is measured over a period and compared to .

	1 Month	3 Months	6 Months	1 Year	2 Years	3 Years
Return(%)	19.65
Relative Return to S&P 500(%)	14.45

Omega Fund Vi Gp Manager, Ltd. Ownership Network

Ownership Network List of Omega Fund Vi Gp Manager, Ltd.

No Data

Ownership Network Relation of Omega Fund Vi Gp Manager, Ltd.

Omega Fund Vi Gp Manager, Ltd. Owned Company Details

What does Spruce Biosciences Inc do?

Who are the key executives at Spruce Biosciences Inc?

Omega Fund Vi Gp Manager, Ltd. is the 10 percent owner of Spruce Biosciences Inc. Other key executives at Spruce Biosciences Inc include 10 percent owner Novo Holdings A/s , Chief Medical Officer Charlton Ralph William Iii , and director & Chief Executive Officer Javier B. Szwarcberg .

Spruce Biosciences Inc (SPRB) Insider Trades Summary

Over the past 18 months, Omega Fund Vi Gp Manager, Ltd. made no insider transaction in Spruce Biosciences Inc (SPRB). Other recent insider transactions involving Spruce Biosciences Inc (SPRB) include a net sale of 4,172,336 shares made by Novo Holdings A/s ,

In summary, during the past 3 months, insiders sold 0 shares of Spruce Biosciences Inc (SPRB) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 4,172,336 shares of Spruce Biosciences Inc (SPRB) were sold and 0 shares were bought by its insiders, resulting in a net sale of 4,172,336 shares.

Spruce Biosciences Inc (SPRB)'s detailed insider trading history can be found in Insider Trading Tracker table.

Spruce Biosciences Inc Insider Transactions

No Available Data

What does Imago BioSciences Inc do?

Who are the key executives at Imago BioSciences Inc?

Omega Fund Vi Gp Manager, Ltd. is the 10 percent owner of Imago BioSciences Inc. Other key executives at Imago BioSciences Inc include Chief Operating Officer Laura G. Eichorn , See Remarks Michael Arenberg , and director & Chief Executive Officer Hugh Jr Rienhoff .

Imago BioSciences Inc (IMGO) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Imago BioSciences Inc (IMGO) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Imago BioSciences Inc (IMGO) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Imago BioSciences Inc (IMGO)'s detailed insider trading history can be found in Insider Trading Tracker table.

Imago BioSciences Inc Insider Transactions

No Available Data

What does Theseus Pharmaceuticals Inc do?

Who are the key executives at Theseus Pharmaceuticals Inc?

Omega Fund Vi Gp Manager, Ltd. is the 10 percent owner of Theseus Pharmaceuticals Inc. Other key executives at Theseus Pharmaceuticals Inc include director & 10 percent owner Carl L Gordon , director & 10 percent owner Orbimed Advisors Llc , and 10 percent owner Foresite Capital Fund V, L.p. .

Theseus Pharmaceuticals Inc (THRX) Insider Trades Summary

Over the past 18 months, Omega Fund Vi Gp Manager, Ltd. made no insider transaction in Theseus Pharmaceuticals Inc (THRX). Other recent insider transactions involving Theseus Pharmaceuticals Inc (THRX) include a net purchase of 700,000 shares made by Foresite Capital Fund V, L.p. , a net purchase of 479,932 shares made by Orbimed Advisors Llc , and a net purchase of 479,932 shares made by Carl L Gordon .

In summary, during the past 3 months, insiders sold 0 shares of Theseus Pharmaceuticals Inc (THRX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Theseus Pharmaceuticals Inc (THRX) were sold and 1,659,864 shares were bought by its insiders, resulting in a net purchase of 1,659,864 shares.

Theseus Pharmaceuticals Inc (THRX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Theseus Pharmaceuticals Inc Insider Transactions

No Available Data

What does Omega Alpha SPAC do?

Who are the key executives at Omega Alpha SPAC?

Omega Fund Vi Gp Manager, Ltd. is the 10 percent owner of Omega Alpha SPAC. Other key executives at Omega Alpha SPAC include director & 10 percent owner & Chief Executive Officer Otello Stampacchia , 10 percent owner Alpha Management Omega , and Chief Scientific Officer Vincent Ossipow .

Omega Alpha SPAC (OMEG) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Omega Alpha SPAC (OMEG) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Omega Alpha SPAC (OMEG) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Omega Alpha SPAC (OMEG)'s detailed insider trading history can be found in Insider Trading Tracker table.

Omega Alpha SPAC Insider Transactions

No Available Data

What does Lexeo Therapeutics Inc do?

Who are the key executives at Lexeo Therapeutics Inc?

Omega Fund Vi Gp Manager, Ltd. is the 10 percent owner of Lexeo Therapeutics Inc. Other key executives at Lexeo Therapeutics Inc include director & Chief Executive Officer Richard Nolan Townsend , 10 percent owner Lundbeckfond Invest A/s , and 10 percent owner Omega Fund Vi Gp, L.p. .

Lexeo Therapeutics Inc (LXEO) Insider Trades Summary

Over the past 18 months, Omega Fund Vi Gp Manager, Ltd. made no insider transaction in Lexeo Therapeutics Inc (LXEO). Other recent insider transactions involving Lexeo Therapeutics Inc (LXEO) include a net sale of 80,000 shares made by Richard Nolan Townsend , a net purchase of 454,545 shares made by Longitude Capital Partners Iv, Llc , and a net purchase of 454,545 shares made by Omega Fund Vi Gp, L.p. .

In summary, during the past 3 months, insiders sold 15,000 shares of Lexeo Therapeutics Inc (LXEO) in total and bought 0 shares, with a net sale of 15,000 shares. During the past 18 months, 80,000 shares of Lexeo Therapeutics Inc (LXEO) were sold and 1,136,362 shares were bought by its insiders, resulting in a net purchase of 1,056,362 shares.

Lexeo Therapeutics Inc (LXEO)'s detailed insider trading history can be found in Insider Trading Tracker table.

Lexeo Therapeutics Inc Insider Transactions

No Available Data

Omega Fund Vi Gp Manager, Ltd. Mailing Address

Above is the net worth, insider trading, and ownership report for Omega Fund Vi Gp Manager, Ltd.. You might contact Omega Fund Vi Gp Manager, Ltd. via mailing address: 888 Boylston Street, Suite 1111, Boston Ma 02199.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.